Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 April 2025 | Story André Damons | Photo Supplied
Dr Tafadzwa Maramura
Dr Tafadzwa Clementine Maramura is a Senior Lecturer and NRF-Rated Researcher in the Department of Public Administration and Management at the UFS.

With roughly half the world’s population experiencing severe water scarcity for at least part of the year, according to the UN World Water Development Report 2024, a researcher from the University of the Free State (UFS) seeks to understand how South Africa and the rest of the African continent can ensure that every person has access to water.

Besides Dr Tafadzwa Clementine Maramura, Senior Lecturer and NRF-Rated Researcher in the Department of Public Administration and Management at the UFS, research focusing on service delivery, especially delivery of water to the most vulnerable and poorest households, her work also focuses on the water-health nexus. In February she was appointed the Secretary for the Institutional Governance and Regulations Framework – a sub-specialist group for the International Water Association (IWA), becoming the first black African female to be appointed to this position.

According to statistics quoted by Greenpeace, 5.52 billion people out of a population of 7.78 billion in 186 countries face water insecurity, of which, 1.34 billion are Africans, accounting for more than 90% of the continent’s population. The United Nations World Water Development Report 2024: water for prosperity and peace; facts, figures, and action examples state that as of 2022, 2.2 billion people were without access to safely managed drinking water.

 

Research focus

With this, and with the Sustainable Development Goals (SDGs) – especially Goal 6 (clean water and sanitation) – in mind, Dr Maramura seeks to understand how South Africa and the rest of Africa can ensure that everyone gets access to this particular resource. “My research focuses on water governance and sustainable service delivery, public policies, and the green economy in the African, as well as the South African, context. What I found is interesting and really saddening at the same time. When you break it down, you realise that one in every three people in Africa don’t have access to potable water.

“Water is a basic human right, you can survive without electricity and other luxuries, but not without water. Each time you brush your teeth or flush your toilet with at least 15 litres of clean water or you are watering your garden with clean water, there are people that actually don’t have access to basic drinking water,” says Dr Maramura.

She is also investigating what the government is doing to ensure it delivers on this service it is mandated to, as South Africa has all the policies in place, and the best constitution in the world, but still the poor and most vulnerable communities do not have water.

“Access to clean water is not just a basic need; it is a matter of dignity, equality, and survival. As a young African woman, through my research, I see first-hand how the burden of water scarcity falls disproportionately on women and girls, robbing us as women, of education, economic opportunities, and health.

“But we are not just victims – we are leaders in this fight. By empowering women and investing in sustainable water solutions, we can transform our communities and break the cycle of poverty. The time for action is now because water is life, and every African deserves it.”

 

The water-health nexus

Dr Maramura has book chapters coming out in June this year that focus on the water-health nexus in failed states, thereby merging SDG 3 and 6 on health and water respectively. Water plays an indispensable role in the world as it is important for accomplishing several other SDGs, such as zero hunger, poverty eradication, good health and well-being, and affordable and clean energy. It all depends on the achievement of goal 6.

Says Dr Maramura: “You cannot solve problems in isolation; you cannot look at the water problem in isolation. If you have a water problem, you have a health and education problem because kids can’t go to school if there is no water. Hospitals can’t function when there is no water.

“SDG 3 speaks to health and SDG 6 speaks to water and that is where the nexus is, nexus meaning connection between water and health. How can we ensure that we merge the two together and ensure researchers working on health and water can find common ground to address any challenges arising from the lack of water so that we don’t have these health issues?”

South Africa is an upper-middle-income country but still struggles to deliver potable water to everyone and many communities in the country still rely on ventilated pit latrines due to limited access to modern sanitation facilities. With the deadline for achieving the 17 SDGs only five years away, South Africa is at risk of failing to achieve the SDGs.

 

Solving the water problems

According to Dr Maramura, there is no magic wand that can be used to solve all the country's water problems, but a collaborative and comprehensive effort is needed. “There is work that needs to be done. The government, private sector, the communities, as well as other role players need to work together. South Africa is a water-stressed country with rainfall below the global average. We realised that we have scarce groundwater resources.

“The community needs to understand, participate, and be aware of how much damage we can do by just drilling boreholes and digging wells. The private sector needs to know what it is that they can do to ensure that they also play a part through their corporate social responsibility and philanthropic dimensions in assisting the community.”

From the government side, she says, the policies are there so the government needs to consult with the communities, the private sector, and all other relevant stakeholders. They need to involve affected communities and after consultations, they need to engage these communities because they understand their problem best.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept